文献速递生殖医学

再次接受ART治疗以生育第二个孩子的累积活产率

Cumulative live birth rates for women returning to ART treatment for a second ART-conceived child.
PubMed 文献 · Hum Reprod · 2020-01-01

结果显示,六周期后累积活产率因起始方案不同在50.5%-88.1%之间,既往冻胚起始者成功率更高。

要点

  • 六周期后累积活产率:冻胚起始60.9%-88.1%,新促排周期50.5%-69.8%
  • ≥35岁、等待≥3年或首次需更多促排周期/双胚移植者再次活产几率降低

核心结论

  • 女性返回ART治疗生育第二个孩子的累积活产率取决于起始方案和脱失假设,六周期后在50.5%至88.1%之间。
  • 以既往冻胚起始治疗者的活产率 consistently 优于新促排周期者。

主要发现

  • 六周期后累积活产率:冻胚起始保守60.9%(95%CI 60.0-61.8%),最优88.1%(95%CI 86.7-89.5%),IPW 87.2%(95%CI 86.2-88.2%)。
  • 新促排周期累积活产率:保守50.5%(95%CI 49.0-52.0%),最优69.8%(95%CI 67.5-72.2%),IPW 68.1%(95%CI 67.3-68.9%)。
  • ≥35岁、等待至少3年返回治疗、或首次需更多促排周期或双胚移植者的调整后第二次活产几率降低。

临床怎么用

  • 可利用年龄别成功率对希望生育第二个ART孩子的女性进行个体化咨询。
  • 咨询时应告知起始方案(冻胚 vs 新促排)对累积活产率的差异。

局限性

  • 估计未完全考虑个体预后因素,包括不孕持续时间、BMI和卵巢储备。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

STUDY QUESTION: What are the success rates for women returning to ART treatment in the hope of having a second ART-conceived child. SUMMARY ANSWER: The cumulative live birth rate (LBR) for women returning to ART treatment was between 50.5% and 88.1% after six cycles depending on whether women commenced with a previously frozen embryo or a new ovarian stimulation cycle and the assumptions made regarding the success rates for women who dropped-out of treatment. WHAT IS KNOWN ALREADY: Previous studies have reported the cumulative LBR for the first ART-conceived child to inform patients about their chances of success. However, most couples plan to have more than one child to complete their family and, for that reason, patients commonly return to ART treatment after the birth of their first ART-conceived child. To our knowledge, there are no published data to facilitate patient counseling and clinical decision-making regarding the success rates for these patients. STUDY DESIGN, SIZE, DURATION: A population-based cohort study with 35 290 women who commenced autologous (using their own oocytes) ART treatment between January 2009 and December 2013 and achieved their first treatment-dependent live birth from treatment performed during this period. These women were then followed up for a further 2 years of treatment to December 2015, providing a minimum of 2 years and a maximum of 7 years of treatment follow-up. PARTICIPANTS/MATERIALS, SETTING, METHODS: Cycle-specific LBR and cumulative LBR were calculated for up to six complete ART cycles (one ovarian stimulation and all associated transfers). Three cumulative LBR were calculated based on the likelihood of success in women who dropped-out of treatment (conservative, optimal and inverse probability-weighted (IPW)). A multivariable logistic regression model was used to predict the chance of returning to ART treatment for a second ART-conceived child, and a discrete time logistic regression model was used to predict the chance of achieving a second ART-conceived child up to a maximum of six complete cycles. The models were adjusted for patient characteristics and previous and current treatment characteristics. MAIN RESULTS AND THE ROLE OF CHANCE: Among the women who had their first ART-conceived live birth, 15 325 (43%) returned to treatment by December 2015. LBRs were consistently better in women who recommenced treatment with a previously frozen embryo, compared to women who underwent a new ovarian stimulation cycle. After six complete cycles, plus any surplus frozen embryos, the cumulative LBR was between 60.9% (95% CI: 60.0-61.8%) (conservative) and 88.1% (95% CI: 86.7-89.5%) (optimal) [IPW 87.2% (95% CI: 86.2-88.2%)] for women who recommenced treatment with a frozen embryo, compared to between 50.5% (95% CI: 49.0-52.0%) and 69.8% (95% CI: 67.5-72.2%) [IPW 68.1% (95% CI: 67.3-68.9%)] for those who underwent a new ovarian stimulation cycle. The adjusted odds of a second ART-conceived live birth decreased for women ≥35 years, who waited at least 3 years before returning to treatment, or who required a higher number of ovarian stimulation cycles or double embryo transfer to achieve their first child. LIMITATIONS, REASONS FOR CAUTION: Our estimates do not fully account for a number of individual prognostic factors, including duration of infertility, BMI and ovarian reserve. WIDER IMPLICATIONS OF THE FINDINGS: This is the first study to report success rates for women returning to ART treatment to have second ART-conceived child. These age-specific success rates can facilitate individualized counseling for the large number of patients hoping to have a second child using ART treatment. STUDY FUNDING/COMPETING INTEREST(S): No funding was received to undertake this study. R. Paul and O. Fitzgerald have nothing to declare. D. Lieberman reports being a fertility specialist and receiving non-financial support from MSD and Merck outside the submitted work. C. Venetis reports being a fertility specialist and receiving personal fees and non-financial support from MSD, personal fees and non-financial support from Merck Serono and Beisins and non-financial support from Ferring outside the submitted work. G.M. Chambers reports being a paid employee of the University of New South Wales, Sydney (UNSW) and Director of the National Perinatal Epidemiology and Statistics Unit (NPESU), UNSW. The Fertility Society of Australia (FSA) contracts UNSW to prepare the Australian and New Zealand Assisted Reproductive Technology Database (ANZARD) annual report series and benchmarking reports. TRIAL REGISTRATION NUMBER: NA.

来源:Hum Reprod,查看原文。版权归原作者所有。

引用

  1. Paul RC, Fitzgerald O, Lieberman D, et al. Cumulative live birth rates for women returning to ART treatment for a second ART-conceived child. Hum Reprod. 2020. PMID: 32380547. doi:10.1093/humrep/deaa030

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。